Abiopharma

IMMUNIC, INC. (IMUX) Announces Clinical Trial Update IMMUNIC, INC. (IMUX) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: period, program
• Diseases/Conditions: neurologic diseases, Immunic
• Clinical Stage: Phase 3 program, Phase 3
• Collaboration: Board
  • expected by year-end and the planned initiation of our confirmatory Phase 3 program in progressive MS, we are executing towards a series of milestones that have the potential to define Immunic’s next phase of growth. Elena’s experience building and advising high-growth biopharma companies will be invaluable as we continue to unlock vidofludimus calcium’s potential across MS patient populations. I look forward to working closely with her as we move into this next phase.” Ms. Ridloff brings more than 20 years of leadership experience in finance, corporate development, investor relations, and capital markets across the biopharmaceutical industry. She currently serves as Chief Financial Officer at Sionna Therapeutics. Previously, Ms. Ridloff served as Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals, where she led the finance organization and played a key role in the company's commercial growth, business development, pipeline expansion, and successfully raising $600 million in capital. Earlier in her career, she established and led the investor relations function at Alexion Pharmaceuticals, was Chief Executive Officer of BIOVISIO, an independent consulting firm serving the life sciences industry, and served as a Managing Director at Maverick Capital, a hedge fund, leading healthcare and life sciences investments. Ms. Ridloff also serves on the Board of Directors of Kymera Therapeutics, where she chairs the Audit Committee, and previously served on the Board of Directors of Kronos Bio. She holds a B.A. in History and Sociology of Science from the University of Pennsylvania and is a CFA charterholder. “I am honored to join Immunic’s Board at such an exciting stage in the company’s evolution,” said Ms. Ridloff. ”Immunic has assembled an exceptional team with deep expertise in MS and is advancing a differentiated oral program designed with the potential to become a meaningful franchise opportunity spanning both relapsing and progressive forms of MS. With important clinical milestones ahead, I look forward to working alongside the Board and management team to help advance vidofludimus calcium and support the successful execution of the company’s long-term strategy.” About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026